Bronx Transthyretin Amyloid Cardiomyopathy Database

Running, not enrolling

Conditions studied: Transthyretin Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy

In brief

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

Key facts

Study ID

NCT06257485

Run by

Montefiore Medical Center

People needed

476

Starts

2023-09-23

Expected to finish

2026-12-01

Last updated by the study team

2026-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All adult patients referred for PYP SPECT at Montefiore Medical Center between 2014 and 2023

You may not qualify if…

• Did not have a transthoracic echocardiogram in our medical records

Where it is running

• Montefiore Health System — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.